Overview

Efficacy and Safety of HRS-1780 Tablets and Henagliflozin Proline Tablets in Patients With Chronic Kidney Disease

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to evaluate the efficacy of HRS-1780 tablets or Henagliflozin Proline tablets in patients with chronic kidney disease by evaluating UACR change from baseline to Week 13
Phase:
PHASE2
Details
Lead Sponsor:
Shandong Suncadia Medicine Co., Ltd.